97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients...
Read More
Merck has released first presentations of data from C-EDGE phase III clinical trial of...
Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson...
Bidness Etc takes a look at how Merck’s new drug is different from the...
More than 70% of people with chronic genotype 1 hepatitis C who did not...
An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response...
VIENNA — An investigational drug combination had high efficacy among patients with cirrhosis associated...
With Merck & Co. poised to disrupt competitors with new hepatitis C drugs, rivals...
Results of trials of antivirals to treat hepatitis C infections are dominating the proceedings...
The use of interferon to treat hepatitis C infections has fallen out of favor...